Evidence map›Paper›PMID 40879325›Full record

ReviewPediatric blood & cancer2025

New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee.

Jessica D Daley, Susan L Whiteway, Christine M Heske, Filemon S Dela Cruz, Sarah B Whittle, Sarah Cohen-Gogo, Anderson B Collier, Ajay Gupta, Joyce Ohm, Andrew Clark and 8 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Tissue-Specific Expression of the EWSR1::FLI1 Fusion Protein IdentifiesInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jessica D DaleyDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Susan L WhitewayDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0003-3496-6252
Christine M HeskePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Filemon S Dela CruzDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Sarah B WhittleTexas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas, USA.
Sarah Cohen-GogoDivision of Hematology/Oncology, Department of Pediatrics, Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-8852-1104
Anderson B CollierNemours Children's Health, Jacksonville, Florida, USA.
Ajay GuptaRoswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID https://orcid.org/0000-0001-6074-9847
Joyce OhmRoswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Andrew ClarkDivision of Pharmacy Services, Children's National Hospital, Washington, District of Columbia, USA.
Alice SoragniDepartment of Orthopedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Elizabeth LawlorBen Towne Center for Childhood Cancer & Blood Disorders Research, Seattle Children's Research Institute, University of Washington, Seattle, Washington, USA.
Bhuvana SettyDivision of Pediatric Hematology/Oncology/Bone Marrow Transplant, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-6054-817X
Patrick J GroharDepartment of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
Katie JanewayBoston Children's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6000-3594
Damon R ReedDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Emily K SlotkinDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.ORCID https://orcid.org/0000-0002-4463-5759
Kelly M BaileyDepartment of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-3925-3243

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180886NCTN Operations Center Grant U10CA180886
6 · The paper itself

Abstract

Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.

Indexed as

Antineoplastic AgentsBone NeoplasmsSarcoma, EwingChildClinical Trials as TopicClinical Trials, Phase II as TopicHumansAntineoplastic AgentsAYAEwing sarcomarelapse

Identifiers

PMID40879325
PMCPMC13092261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.